On being asked about the unique name, Federica Mazza, Creative Director at LEMUDA, explains “The name LEMUDA is a new word which is created by mixing the word ’Fashion’ from Arabic -which is ’Moudah’- and words for fashion in Italian ’La Moda’ and French ’Le Mode’. We decided our name as ’LeMuda’ – which gives a good combination of Euro–Arab tone for our site as these are also the locations where we have started our operations for this site.”

With operations from the fashion capital, Milan and in Dubai, this fashionable online shopping website, with a multi-lingual Arabic and English interface understands the region’s thirst for new international brands. Fashion-savvy shoppers can buy their favorite products on LEMUDA through the two available channels; catalog & special sales. The online LEMUDA catalog features end of season premium brands for women at approximately 50% off the retail price. The time-limited special sales last for 3-4 days and offer highly discounted men’s and women’s clothing, children’s wear and toys, home décor, beauty and travel products from several other top brands up to 80% off. Thus, unlike any other online player in the sector, LEMUDA.COM offers a new format, allowing customers to match designer fashion accessories’ featured in their online catalogue with complementary products highly discounted from the special sales.

“We believe that every woman needs to discover and highlight her unique style. LEMUDA brings the ultimate fashion trends to your door and allows you to make these trends uniquely yours without spending a fortune. We also understand that this region is still wary of online shopping. Therefore, we assure all our customers that we have taken all precautions and made our site a completely safe to shop retail environment and also guarantee all our products to be genuine from its source and in original packaging”, said Federica Mazza. With the Versign Trusted seal on each of its web pages and efficient delivery of its products to the entire GCC, Jordan, Lebanon, Syria & Turkey, LEMUDA definitely has a strong focus on delivering an outstanding customer experience.

In addition to unmatched prices and big names to boast about, what sets LEMUDA apart is their on-call stylist who can help you with handy style tips and in matching clothing with the perfect accessory from the LEMUDA catalog for every occasion. This special styling service is extended to the LEMUDA lady customers to offer them a unique experience.

“We want to project LEMUDA as not just another shopping website but one which provides additional benefits like style hints and advice just like a fashion magazine, but with a personalized service for our customers” says LEMUDA’s creative director. “We are also keen to help users to create their personal style by mixing and matching our high-end accessories with their existing clothes or other easy-to-wear brands. We look to build an interactive community with our customers who can take part, expressing their opinion on our outfit style proposals and sharing their own outfit picks.”

For years, PHYTOMER, the leading French brand of marine based cosmetics, has been a benchmark in the field of contouring thanks to innovative beauty treatment protocols and the use of high-performance marine products with patented ingredients. This expertise is expressed on the wide array of PHYTOMER body treatments that draw effectiveness from varied esthetic methods and specific professional products with marine components.
PHYTOMER widely promotes a scientific approach to nature through Bio-mimicry, the process that is based on analysis of the defense systems of marine plants and algae, alongside the identification of marine ingredients which are capable of reproducing these systems within the skin. All PHYTOMER beauty products and treatments are systematically tested and designed in a way to completely respect the well-being and serenity of the guests. Specific ingredients combined with exclusive PHYTOMER treatment protocols guarantee high-end esthetic solutions.
Backed by its scientific expertise, PHYTOMER has developed to date innovative, intensely relaxing and extremely active specialist body treatments portfolio which also includes a choice of 3 high-performance Marine Body Wraps performed in a 60 minutes sessions for a healthy, natural and lasting beauty. Combined with a complete body massage, these perfect, fast-acting wraps help to eliminate toxins, break down fat and re-invigorate the skin tissues.
1- DETOX AND CONTOURING Marine Body Wrap – Eliminates toxins and cellulites, filters tissues and boosts the breakdown of excess fat from problem areas. The skin is left cleansed, refreshed with improved metabolism.
2- INVIGORATING AND REMINERALISING Marine Body Wrap – A complete relaxation and revitalizing experience for those who are tired, stressed and tense
3- FIRMING Marine Body Wrap – A fresh and highly active wrap that promotes elasticity tones and firms the skin and fights skin slackening resulting from weight loss, pregnancy and breastfeeding.
The body wrap protocol differs slightly amongst the 3 types of wraps yet the basic protocol is as follows:
1. Marine Immersion Phase:
The treatment starts with Marine Immersion, a relaxation method which is scientifically proven to provide stress-relieving results. With the soothing scent of PHYTOMER Marine Mist, the guest is immersed in a marine like environment to relax and prepare the body and mind for the treatment.
2. Exfoliation:
In this phase, a dry type of exfoliation is performed. Using a marine sponge or towel, exfoliation is performed over the whole body to release the skin from impurities which improve the overalls circulation. Once all dead skin cells are removed, the circulation is improved and skincare products are better absorbed by the skin, hence a desired result.
3. Body Wrap:
Once the exfoliation is completed, the warm body wrap is then applied all over the guest’s body and then quickly wrapped in a thermoplastic film to insulate the product. The guest then receives a scalp massage for 20 minutes while the body mask is on their body. After the 20 minutes is completed, the guest is escorted to the shower to wash off the excess product.
4. Body Massage:
Finally, the guest returns to the massage table where they will receive a quick massage with a specially adapted PHYTOMER body cream that serves the guest’s main concern.
PHYTOMER – THE OCEAN . THE SCIENCE . THE BEAUTY.

PHYTOMER Marine Body Wraps are available from the following spas:
1. Grosvenor House West Marina Beach, Dubai. Tel: +971 4 3998888
2. The Diplomat Radisson Blu Hotel & Spa, Bahrain. Tel: +973 17 525237
3. Le Meridien Al Aqah Beach Resort, Fujairah. Tel: +971 9 2449000
4. Hilton Dubai Jumeirah, Dubai. Tel: +971 4 3991111
5. Le Meridien Health Spa, Abu Dhabi. Tel: +971 2 6446666
6. Corpofino Spa & Slimming Center, Abu Dhabi. Tel: +971 2 4452800

“Sport is music in the way that it has so many different natural rhythms…when I was recording the athletes I wasn’t really thinking of them in terms of athletes performing a sport, I was thinking of them as people in an orchestra.”Mark Ronson

(BUSINESS WIRE)– Fusing the sounds of sport and music. Anywhere in the World, the anthem for the Coca-Cola London 2012 Olympic campaign, launched globally today. Available for purchase online, the exclusive track is the centerpiece of the brand’s Move to the Beat™ campaign.

Move to the Beat™is designed to bring teens closer to the Olympic Games and to sport in general by engaging them through a fusion of two global teen passions – sport and music. Drawing inspiration from London’s musical heritage, the campaign combines London music with Olympic sport in an effort to connect young people to London 2012.

“The number one passion point for teens is music,” explains Shay Drohan, Senior Vice President of Sparkling Beverages, The Coca-Cola Company. “Through Move to the Beat™, Coca-Cola is inspiring teens around the world to move to the beat of London and come together in the biggest Olympic Games activation in our 84-year partnership.”

Coca-Cola Presents the Beat of London 2012

The creative process behind the production of the track has been brought to life in an engaging hour-long documentary currently airing across the globe. Ronson traveled the world gaining inspiration for the song and meeting young athletes to record the sounds of their sport, before teaming up with UK chart-topper Katy B to provide the vocals.

The athletes whose sounds form the beat of the track are:

• Maria Espinoza, taekwondo athlete from Mexico
• Dayyan Jaffar, archer from Singapore
• Darius Knight, table tennis player from Great Britain
• David Oliver, 110m hurdler from the United States
• Kseniya Vdovina, 400m sprinter from Russia

In this musical experiment, Ronson recorded the array of sounds that each athlete produced while participating in their sport. He used innovative methods to capture the unique sounds of each individual sport, like cycling alongside hurdler David Oliver with a microphone to yield the sound that is produced at the precise moment his feet hit the ground.

“If someone had just sent me a hard disk of all these sounds of athletes, the track wouldn’t have been anywhere near as three-dimensional as it is because I needed those personal experiences with those athletes,” said Mark Ronson. “It’s just so important to be there to see these athletes and spend so much time around them and be in their environment to understand how to make this track.”

A sneak peak of Ronson’s journey is available online.

Global Digital Experience

Teens across the world are invited to be a part of Ronson’s journey and the Games through The Coca-Cola Company’s largest-ever digital program. The Create my Beat desktop application (www.coca-cola.com/theolympics) creates individualized beats by mixing a teen’s personal musical preference and their sporting interest with their online social media footprint. Once created, the personalized experience can be uploaded to The Global Beat, a worldwide online community that brings together individual beats to create an ever-evolving global music collaboration.

Mobile Experience

The My Beatmaker app for smartphones (available for free download online) goes one step further, using groundbreaking ZooZ technology to enable teens to create their Beat through the motion of their phone. The innovative technology detects the movements of the phone and transforms them into unique sounds.

Finally, targeting the largest audiences in countries like China and India, teens can sign up to receive SMS alerts about the campaign that include facts about the athletes and artists and Games related quizzes.

About The Coca-Cola Company

The Coca-Cola Company(NYSE: KO) is the world’s largest beverage company, refreshing consumers with more than 500 sparkling and still brands. Led by Coca-Cola, the world’s most valuable brand, our Company’s portfolio features 15 billion dollar brands including Diet Coke, Fanta, Sprite, Coca-Cola Zero, vitaminwater, Powerade, Minute Maid, Simply, Georgia and Del Valle. Globally, we are the No. 1 provider of sparkling beverages, ready-to-drink coffees, and juices and juice drinks. Through the world’s largest beverage distribution system, consumers in more than 200 countries enjoy our beverages at a rate of 1.8 billion servings a day. With an enduring commitment to building sustainable communities, our Company is focused on initiatives that reduce our environmental footprint, support active, healthy living, create a safe, inclusive work environment for our associates, and enhance the economic development of the communities where we operate. Together with our bottling partners, we rank among the world’s top 10 private employers with more than 700,000 system employees. For more information, please visit www.thecoca-colacompany.comor follow us on Twitter at twitter.com/CocaColaCo.

Notes to Editors:

• Users can create and upload their beat to The Global Beat via the mobile web Create my Beat site, with no app download required. Visit: www.coca-cola.com/theolympics.
• Photo caption: LONDON, ENGLAND – MAY 11 2012: Mark Ronson and Katy B perform ‘Anywhere in the World’, the Coca-Cola song for the London 2012 Olympic Games, to celebrate the launch of the single at an exclusive Coca-Cola gig (http://www.youtube.com/watch?v=GdyEkVwKDpc&feature=plcp).
• Ronson spent four months travelling the world meeting the athletes. At each visit he experienced their training regimens first hand, recording the sounds of their sports in unique and unconventional ways, including:
  • Maria Espinoza, Taekwondo (Mexico) – The song opens with the voice of her coach signaling the start of the fight. Her distinctive vocal expressions as she spars with her opponent and the sounds of her kicks punctuate the song.
  • Dayyan Jaffar, Archery (Singapore) – The sounds of the arrow hitting the target is, as Mark Ronson describes, as clean as the sound of a kick drum.
  • Darius Knight, Table Tennis, (Great Britain) – Darius’ grunts add a human element to the song, as well as the percussive tapping of table tennis balls.
  • David Oliver, 110 metre hurdles (United States) – David’s feet hit the ground forming a rhythm.
  • Kseniya Vdovina, 400 metres (Russia) – Her heartbeat is recorded at a precise rate of 120 beats per minute, to match the song’s beats per minute.

Photos/Multimedia Gallery Available: http://www.businesswire.com/cgi-bin/mmg.cgi?eid=50280764&lang=en

Photo Caption:

Image 1: LONDON, ENGLAND – MAY 11 2012: Mark Ronson and Katy B perform ‘Anywhere in the World’, the Coca-Cola song for the London 2012 Olympic Games, to celebrate the launch of the single at an exclusive Coca-Cola gig (http://www.youtube.com/watch?v=GdyEkVwKDpc&feature=plcp). (Photo: Business Wire)

Contacts

The Coca-Cola Company

Kate Hartman, +01 404.676.2683

(BUSINESS WIRE)– A.M. Best Co. is pleased to announce the opening of its new office in the Dubai International Finance Centre (DIFC) in Dubai, UAE. The new office, located in Tower 2, Currency House, DIFC, will operate as A.M. Best MENA, South & Central Asia, servicing clients throughout the region and developing new relationships to continue to grow its insurance ratings franchise. Rating analytics will continue to be performed by teams based in London and Hong Kong. A.M. Best obtained the necessary approvals to establish within the DIFC in February.

A.M. Best is the leading international rating agency with a specialist focus on the worldwide insurance industry, including the Takaful sector. Best’s Credit Ratings are recognised by users as the benchmark for assessing the financial strength of insurance-related organisations and the credit quality of their obligations. In recent years, A.M. Best has greatly expanded its coverage of the Middle East and North Africa region as the market evolves and ratings become more widely used.

Abdulla Mohammed Al Awar, CEO of DIFC Authority, said, “Amidst the constant development in the world of financial services there has been a rapid growth in the insurance industry. To provide comfort to policy holders, companies in that industry need reputable rating agencies of A.M. Best’s calibre to assess their creditworthiness. We are very proud to have the pioneers of the concept of financial ratings that specialise in insurance establish their regional presence in DIFC. We look forward to supporting their business here and working with them to further develop the financial services industry in the region.”

Vasilis Katsipis, general manager – market development, will be responsible for the office in Dubai and will report to Nick Charteris-Black, managing director, market development A.M. Best – EMEA.

“We look forward to joining the other international companies in what has become a major financial centre for the region,” said Dr Roger Sellek, chief executive officer of A.M. Best – EMEA and Asia Pacific. “The opening of A.M. Best MENA, South & Central Asia is an important step in A.M. Best’s commitment to being a truly global rating agency servicing the needs of the (re)insurance industry throughout the world including the growth economies in this important region.”

The full address of A.M. Best’s new office in Dubai, UAE is:

A.M. Best MENA, South & Central Asia, Office 102, Tower 2, Currency House, DIFC. P. O. Box 506617, Dubai, United Arab Emirates.

Tel: + 971 (0) 43 752 782

Founded in 1899, A.M. Best Company is the world’s oldest and most authoritative insurance rating and information source. For more information, visit www.ambest.com.

Copyright © 2012 by A.M. Best Company, Inc.ALL RIGHTS RESERVED.

Photos/Multimedia Gallery Available: http://www.businesswire.com/cgi-bin/mmg.cgi?eid=50280992&lang=en

Photo Caption:

Image 1: Left to right: Mohammed Juma, Head of Corporate Communications, DIFC Authority; Nick Charteris Black, Managing Director, Market Development, A.M Best–EMEA; Abdulla Mohammed Al Awar, CEO, DIFC Authority; Dr Roger Sellek, CEO, A.M. Best–EMEA and Asia Pacific; and Vasilis Katsipis, General Manager, Market Development, A.M. Best–MENA, South & Central Asia (Photo: Business Wire)

Contacts

A.M. Best Co.

Nick Charteris-Black

Managing Director, Market Development – EMEA

+(44) 20 7397 0284

nick.charteris-black@ambest.com

Vasilis Katsipis

General Manager, Market Development – MENA, South & Central Asia

+ 971 (0) 43 752 782

vasilis.katsipis@ambest.com

Edem Kuenyehia

Assoc. Director, Market Development & Communications

+(44) 20 7397 0280

edem.kuenyehia@ambest.com

DULUTH, Ga. – Thursday, May 17th 2012 [ME NewsWire]

(BUSINESS WIRE)– AGCO, Your Agriculture Company (NYSE: AGCO), a worldwide manufacturer and distributor of agricultural equipment, celebrated a groundbreaking ceremony for its African Master Parts Distribution Centre together with its South African distribution partner, Barloworld, in Johannesburg on Monday. “Africa offers tremendous growth opportunities in the agricultural equipment sector,” said Martin Richenhagen, Chairman, President and CEO of AGCO. “AGCO is committed to growing its presence within Africa by investing in distribution infrastructure and new training sites. Our new warehouse will allow us to better serve our customers in Sub-Saharan Africa.”

The new AGCO Parts Distribution Centre will be located close to the O.R. Tambo International Airport in Johannesburg with optimal logistical connections. A wide range of up to 40,000 parts will be stocked locally to significantly improve order response times and machine uptime for AGCO’s African customers. “Investing in AGCO’s after-sales service infrastructure in Africa allows us to be closer to the market and provide better service levels to our local distribution partners and customers,” explained Hubertus Mühlhäuser, Senior Vice President, General Manager, Europe, Africa & Middle East.

“A continent like Africa has significant potential for growth in the agricultural sector. With 11 percent of the world’s arable land, much of which is uncultivated, Africa will benefit from modern, mechanized farming techniques,” continued Hubertus Mühlhäuser. “Overall, AGCO plans to invest up to $100m USD in its Africa business over the next few years. The new master parts warehouse in Johannesburg is a first step to improve our after-sales infrastructure for African markets.” AGCO’s technology-driven products will contribute to the modernization of the African agricultural market, and the local presence will allow AGCO to better serve African customers with high quality products and services.

With over 50 years of experience in Africa through its Massey Ferguson tractor brand, AGCO already leverages alliances with governments, foreign investors and donors to improve agricultural practices in Africa. AGCO plans to fund the development of Model Farms and Training Centers in Zambia, Ethiopia, Morocco and South Africa that will allow local farmers and dealers to be trained on new farming methods and technology.

The construction of AGCO’s African master parts warehouse will be completed by the end of 2012. In addition to supporting AGCO’s distributors in Southern Africa, AGCO Parts shipments to Barloworld’s dealer network will also be prepared from the new AGCO warehouse. The joint approach will allow Barloworld to offer an even better service to its customers due to the expanded range of locally stocked parts.

ABOUT AGCO

AGCO, Your Agriculture Company, (NYSE: AGCO), is a global leader focused on the design, manufacture and distribution of agricultural machinery. AGCO supports more productive farming through a full line of tractors, combines, hay tools, sprayers, forage equipment, tillage, implements, grain storage and protein production systems, as well as related replacement parts. AGCO products are sold through four core machinery brands, Challenger®, Fendt®, Massey Ferguson® and Valtra® and are distributed globally through 3,100 independent dealers and distributors in more than 140 countries worldwide. Retail financing is available through AGCO Finance for qualified purchasers. Founded in 1990, AGCO is headquartered in Duluth, GA, USA. In 2011, AGCO had net sales of $8.8 billion. http://www.AGCOcorp.com

Safe Harbor Statement

Statements which are not historical facts, including expectations regarding the development and sales of products in this region, are forward-looking and subject to risks that could cause actual results to differ materially from those suggested by the statements. These risks include possible declines in demand for products as a result of weather, demand and other conditions that impact farm income, actions by producers of competitive products, and the general risks attendant to acquisitions. Further information concerning these and other factors is included in AGCO’s filings with the Securities and Exchange Commission, including its Form 10-K for the year ended December 31, 2011. AGCO disclaims any obligation to update any forward-looking statements except as required by law.

Photos/Multimedia Gallery Available: http://www.businesswire.com/cgi-bin/mmg.cgi?eid=50280547&lang=en

Photo Caption:

Image 1: Massey Ferguson Model 6485 ground breaking ceremony at Pomona, Johannesburg People (from left to right): Boris Schoepplein, Vice President Parts Europe, Africa & Middle East (AGCO); Godfried Heydenrych, Director Barloworld Handling (Barloworld); Nuradin Osman, Special Assistant to the Chairman and Director Operations Africa & Middle East (AGCO); Charles van Niekerk, General Manager MF and Challenger (Barloworld)

Contacts

AGCO

Rebecca Fabian, +1.646.415.8518

rf@stockheim-media.com

DUBAI, United Arab Emirates – Thursday, May 17th 2012 [ME NewsWire]

(BUSINESS WIRE)– The Wells Fargo International Group, part of Wells Fargo & Company (NYSE:WFC), announced that Shoar Hassan has joined its Global Financial Institutions (GFI) group as regional manager for Middle East and North Africa. Based in Dubai, Hassan reports to Dilek Mutus, head of Wells Fargo’s GFI business for Turkey, Russia, Middle-East and Sub-Continent India.

Serving more than 3,000 banks in 130 countries, Wells Fargo’s GFI business provides payments, collections, trade services, deposits, credit, foreign exchange, liquidity and investment management to financial institutions and multilateral agencies across the globe. With extensive experience managing debt capital markets, loan distribution and investment products, Shoar will be responsible for strengthening Wells Fargo’s relationships with select commercial banks and sovereign wealth funds in the region.

“We are excited to welcome Shoar to our team and are confident that his deep knowledge and industry expertise will strengthen Wells Fargo’s GFI business in the region,” said Mutus.

Prior to joining Wells Fargo, Shoar was with BNP Paribas’ Financial Institutions Group as executive director and senior banker for the Middle East. He is the former director of ABN Amro’s Financial Institutions Group and has held variations positions at Citibank and ABN Amro in Pakistan in Corporate and Correspondent Banking as well as Global Transaction Services. Shoar has an M.B.A. degree in finance from Lahore University of Management Sciences in Pakistan.

The Wells Fargo International Group provides small businesses, corporations, financial institutions, multilateral organizations and individuals with a wide range of international solutions from more than 35 global locations, including branches in Hong Kong, London, Seoul, Shanghai, Singapore, Taipei, Tokyo and the Cayman Islands.

About Wells Fargo & Company

Wells Fargo & Company (NYSE: WFC) is a nationwide, diversified, community-based financial services company with $1.3 trillion in assets. Founded in 1852 and headquartered in San Francisco, Wells Fargo provides banking, insurance, investments, mortgage, and consumer and commercial finance through more than 9,000 stores, 12,000 ATMs, the Internet (wellsfargo.com), and other distribution channels across North America and internationally. With more than 270,000 team members, Wells Fargo serves one in three households in America. Wells Fargo & Company was ranked No. 23 onFortune’s 2011 rankings of America’s largest corporations. Wells Fargo’s vision is to satisfy all our customers’ financial needs and help them succeed financially.

Photos/Multimedia Gallery Available: http://www.businesswire.com/cgi-bin/mmg.cgi?eid=50280979&lang=en

Contacts

Wells Fargo & Company

Katie Ellis, 415-222-3767 (Media)

kathryn.d.ellis@wellsfargo.com

The BILANMATIC XG features: a CAN-Bus, which allows efficient communication between test chassis and the console thus improving accuracy in measurement procedures, a 22” flat screen of excellent graphic quality, a USB port to provide fast & easy connections for peripheral test equipments. The BILANMATIC XG test lane is also configured for Remote Assistance, a new service which enables engineers to access your test lane from a distance for instant settings update. The lane may be split into several test bays, allowing simultaneaous testing of multiple vehicles: 16 possible users via 16 infrared remote controls (patented by Muller Bem). The lane is perfect for drive-through testing. 

The BILANMATIC XG is part of a comprehensive range of electronic diagnostic devices, car repair equipment and test lanes provided by Actia Muller. The range meets the most stringent demands of all key players in the global market. Leading car manufacturers, vehicle inspection networks and automotive customer service players patronize Actia Muller in their day-to-day business. Actia Muller has established its presence in G.C.C. area with Panirez FZE and is looking forward to the launch of its innovative vehicle inspection equipment in G.C.C. as part of an initiative to ensure driver safety nationwide. Actia Muller test lanes have already been deployed in E.A.U., K.S.A. and States of Qatar. 

About Actia Group

Actia Group is an international group, specialised in added value electronic equipment destined for the buoyant Automotive and Telecommunications markets. Its headquarters are based in the south of France. The Automotive division (80% of the total turnover of Actia Group ) is a major player in the design, the manufacturing and the diagnostics of small and mid-runs on board systems for vehicles. The group has 2500 employees and a turnover of €300m in 2012 with 15% invested in R&D activities.

About Actia Muller
Actia Muller is a fully-owned subsidiary of ACTIA Automotive, a member of the French group Actia Group. We offer new solutions for the electronic diagnosis, the mechanical testing and car inspection all around the world thanks to our international network of 33 subsidiaries and agents. Actia Muller has 165 emplyees and 35000 customers worldwide and a €36m turnover in 2012 with 50% of turnover made abroad and 15% of it invested in R&D activities.

http://www.actiamuller.com/

INGELHEIM, Germany – Thursday, May 17th 2012 [ME NewsWire]

(BUSINESS WIRE)– Among the numerous abstracts being presented by Boehringer Ingelheim at the 48th Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago, June 1-5, 2012, the company will present results from the highly anticipated pivotal LUX-Lung 3 Phase III clinical trial. LUX-Lung 3 investigated afatinib*, and was the largest and most robust trial to date in first-line EGFR mutation positive, advanced, metastatic non-small cell lung cancer (NSCLC) patients,1 and the first study to use pemetrexed / cisplatin as a comparator.

The study results will shed light on a distinct and specific NSCLC patient population: those with EGFR mutations. EGFR mutations occur in 10-15% of Caucasian and 30-40% of Asian NSCLC patients 2and their presence is a well-established predictive biomarker that provides specific targets for therapeutic intervention in NSCLC. Early mutation testing for EGFR status is important to ensure patients have the opportunity to receive the appropriate personalised therapy immediately after they have been diagnosed with NSCLC.

LUX-Lung 3 ASCO oral presentation information:

Title

Lead Author

Presentation details

LUX-Lung 3: A randomized, open-label, Phase III study of afatinib versus pemetrexed and cisplatin as first-line treatment for patients with advanced adenocarcinoma of the lung harbouring EGFR-activating mutations.

James Chih-Hsin Yang, MD, PhD

Oral Abstract #LBA7500

Date: Monday, June 4 Time: 3:00-3:15 PM CDT

Pemetrexed/cisplatin

“The Annual Meeting of the American Society of Clinical Oncology will be the first time that data from the pivotal LUX-Lung 3 trial will be presented and we are looking forward to the scientific exchange”, said Mehdi Shahidi , M.D., Global Clinical Development Team Leader, Oncology, Boehringer Ingelheim. “The results will be particularly important for EGFR mutation positive patients and underline our commitment to advance personalised care for lung cancer patients”.

Boehringer Ingelheim has initiated two further trials, LUX-Lung 7 and 8, to assess the potential benefit of afatinib* in a head-to-head comparison with erlotinib (in advanced squamous cell carcinoma of the lung) and gefitinib, respectively, in EGFR mutation positive adenocarcinoma of the lung.

Additional Presentations of Boehringer Ingelheim Investigational Compounds

In addition to the LUX-Lung 3 presentation, more than 15 studies assessing Boehringer Ingelheim’s investigational therapies have been selected for presentation at ASCO, demonstrating the company’s strong and ongoing commitment to deliver innovative cancer therapies to patients across a variety of cancer types.

Select Poster Presentations

Title

Lead Author

Poster details

Afatinib*

Data Abstracts

Interim analysis of afatinib monotherapy in patients with metastatic NSCLC progressing after chemotherapy and erlotinib/gefitinib (E/G) in a trial of afatinib plus paclitaxel vs. investigator’s choice chemotherapy following progression on afatinib monotherapy

Martin H. Schuler, MD

Abstract # PS7557

Poster # 9826

Date: Saturday, June 2

Time: 1:15 – 5:15 PM CDT

Afatinib monotherapy in patients with metastatic squamous cell carcinoma of the lung progressing after erlotinib/gefitinib (E/G) and chemotherapy: Interim subset analysis from a phase III trial

Joo-Hang Kim, MD

Abstract # PS7558

Poster # 9825

Date: Saturday, June 2

Time: 1:15 – 5:15 PM CDT

A neoadjuvant, randomized, open-label phase II trial of afatinib (A) vs. trastuzumab (T) vs. lapatinib (L) in patients (pts) with locally advanced HER2-positive breast cancer (BC).

Mothaffar F. Rimawi, MD

Abstract # PS606

Poster # 9823

Date: Saturday, June 2

Time: 8:00 AM – 12:00 PM CDT

Trial In Progress Abstracts

LUX-breast 1: A randomized, phase III trial of afatinib and vinorelbine versus trastuzumab and vinorelbine in patients with HER2-overexpressing metastatic breast cancer (MBC) failing one prior trastuzumab treatment.

Nadia Harbeck, MD, PhD

Abstract #TPS649

Poster #15D

Date: Saturday, June 2 Time: 8:00 AM – 12:00 PM CDT

LUX-breast 2: A Phase II, open-label study of oral afatinib in HER2-overexpressing metastatic breast cancer (MBC) patients (pts) who progressed on prior trastuzumab (T) and/or lapatanib (L).

Tamas Hickish, MD

Abstract # TPS651

Poster #15F

Date: Saturday, June 2 Time: 8:00 AM – 12:00 PM CDT

LUX-breast 3: A randomised phase II study of afatinib alone or with vinorelbine versus investigator’s choice of treatment in patients (pts) with HER2-positive breast cancer (BC) with progressive brain metastases (BM) after trastuzumab or lapatinib-based therapy.

Heikki Joensuu, MD, Professor

Abstract #TPS647

Poster #15B

Date: Saturday, June 2 Time: 8:00 AM – 12:00 PM CDT

LUX-head and neck 1: A phase III, randomized trial of afatinib versus methotrexate (MTX) in patients (pts) with recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC) who progressed after platinum-based therapy.

Jean-Pascal H. Machiels, MD, PhD

Abstract # PS5598

Poster #32H

Date: Saturday, June 2

Time: 1:15 – 5:15 PM CDT

LUX head and neck 2: A randomized, double-blind, placebo-controlled, phase III study of afatinib as adjuvant therapy after chemoradiation in primarily unresected, clinically high-risk, head and neck cancer patients.

Barbara Burtness, MD

Abstract # TPS5599

Poster # 33A

Date: Saturday, June 2

Time: 1:15 – 5:15 PM CDT

Nintedanib*

TRICC-c: BIBF 1120 versus placebo in patients receiving oxaliplatin plus fluorouracil and leucovorin (mFOLFOX6) for advanced, chemorefractory metastatic colorectal cancer (mCRC)—A multicenter, randomized phase II trial in progress.

Andreas Berger, MD

Abstract # TPS3636

Poster # 39A

Date: Monday, June 4 Time: 8:00 AM – 12:00 PM CDT

Volasertib*

Phase I trial of the polo-like kinase (Plk) inhibitor volasertib (BI 6727) combined with cisplatin or carboplatin in patients with advanced solid tumors.

Herlinde Dumez

Abstract # 3018

Poster #10

Date: Saturday, June 2

Time: 1:15 – 5:15 PM CDT

Notes to Editors

About Lung Cancer

Lung cancer is the most common and most deadly form of cancer in the world: it accounts for 1.6 million new cancer cases annually. Because of its poor prognosis, 1.38 million deaths each year are attributable to lung cancer.3 Overall, lung cancer is the cause of 18% of all cancer deaths.3 Thirteen percent of all new cases of cancer are lung cancers4 and smoking is attributed as the main cause.5

About Afatinib*

Afatinib* is an irreversible ErbB Family Blocker which inhibits signal transduction of all kinase receptors from the ErbB Family2, which is known to play a critical role in the growth and spread of the most pervasive cancers and cancers associated with high mortality (lung, breast, and head & neck cancers). A mutation of the Epidermal Growth Factor Receptor (EGFR, also referred to as ErbB1) is found in 10-15% of Caucasian and in 30-40% of Asian NSCLC patients2.

About the Afatinib* Clinical Trial Program

The LUX-Lung studies evaluate the use of afatinib* in various settings of advanced NSCLC, including in patients harbouring EGFR mutations and those with recurrent disease. These trials include:

LUX-Lung 1, a Phase IIb/III trial investigating afatinib plus best supportive care (BSC) versus placebo plus BSC in NSCLC patients who were previously treated with first-line chemotherapy and the reversible EGFR TKIs erlotinib or gefitinib. This trial is complete and no longer recruiting.
LUX-Lung 2, a Phase II trial evaluating afatinib in NSCLC patients with EGFR mutations (EGFR M+), either treatment-naïve or after one line of treatment with chemotherapy. This trial is complete and no longer recruiting.
LUX-Lung 3, a Phase III trial investigating afatinib as a first-line treatment in patients with advanced NSCLC with EGFR mutations. This trial is complete and no longer recruiting.
LUX-Lung 4, a Phase I/II trial of afatinib in NSCLC patients who have progressed after conventional EGFR-TKI treatment. This trial is ongoing, but no longer recruiting.
LUX-Lung 5, a global Phase III trial in patients previously treated with erlotinib or gefitinib and chemotherapy. This is the first randomized Phase III trial investigating whether patients who initially benefit from treatment with afatinib alone may further benefit from afatinib beyond progression when given in combination with chemotherapy. This trial is ongoing, but no longer recruiting.
LUX-Lung 6, a Phase III trial investigating the efficacy and safety of afatinib compared to standard chemotherapy for first-line treatment of NSCLC patients with EGFR mutations. This trial is ongoing, but no longer recruiting.
LUX-Lung 7, a Phase IIb trial evaluating afatinib head-to-head versus gefitinib as a first-line treatment in EGFR M+ NSCLC patients. Patient recruitment for this trial was recently initiated.
LUX-Lung 8, a Phase III trial evaluating afatinib head-to-head versus erlotinib in second-line treatment of squamous cell carcinoma of the lung. Patient recruitment for this trial was recently initiated.

For more information on these trials, please visit www.clinicaltrials.gov.

About Boehringer Ingelheim in Oncology

Building on scientific expertise and excellence in the fields of pulmonary and cardiovascular medicine, metabolic disease, neurology, virology and immunology, Boehringer Ingelheim has embarked on a major research programme to develop innovative cancer drugs. Working in close collaboration with the international scientific community and a number of the world’s leading cancer centres, Boehringer Ingelheim’s commitment to oncology is underpinned by using advances in science to develop a range of targeted therapies for various solid tumours and haematological cancers.

The current focus of research includes compounds in three areas: angiogenesis inhibition, signal transduction inhibition and cell-cycle kinase inhibition. Nintedanib* (BIBF 1120) is currently in Phase III clinical development in NSCLC and ovarian cancer. Afatinib* is currently in Phase III clinical development in NSCLC, breast cancer and head and neck cancer. In the area of cell-cycle kinase inhibition, Boehringer Ingelheim is developing an inhibitor of polo-like kinase 1 (Plk1), volasertib*, a protein that is involved in the processes of cell division. The compound is in Phase II development for acute myelogenous leukemia.

Boehringer Ingelheim’s oncology pipeline is evolving and demonstrates the company’s continued commitment to the disease area.

Boehringer Ingelheim

The Boehringer Ingelheim group is one of the world’s 20 leading pharmaceutical companies. Headquartered in Ingelheim, Germany, it operates globally with 145 affiliates and more than 44,000 employees. Since it was founded in 1885, the family-owned company has been committed to researching, developing, manufacturing and marketing novel medications of high therapeutic value for human and veterinary medicine.

As a central element of its culture, Boehringer Ingelheim pledges to act socially responsible. Involvement in social projects, caring for employees and their families, and providing equal opportunities for all employees form the foundation of the global operations. Mutual cooperation and respect, as well as environmental protection and sustainability are intrinsic factors in all of Boehringer Ingelheim’s endeavours.

In 2011, Boehringer Ingelheim achieved net sales of about 13.2 billion euro. R&D expenditure in the business area Prescription Medicines corresponds to 23.5% of its net sales.

For more information please visit: www.boehringer-ingelheim.comand www.thewhiteroom.info

References

1 Abstract no: LBA7500, LUX-lung 3: A randomized, open-label, phase III study of afatinib versus pemetrexed and cisplatin as first-line treatment for patients with advanced adenocarcinoma of the lung harboring EGFR-activating mutations. Oral Presentation at 48th Annual Meeting of the American Society of Clinical Oncology (ASCO) 2012.

2 Jang, T.W. et al. 2009. EGFR and KRAS Mutations in Patients With Adenocarcinoma of the Lung. The Korean Journal of Internal Medicine, March; 24(1), pp.48–54.

3Ferlay J et al. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 2010; EPub Ahead of print.

4Cancer Research UK. UK lung cancer incidence. CancerStats – Key Facts 2009. [Online] Available at: http://info.cancerresearchuk.org/cancerstats/types/lung/incidence/[Last Accessed April 2009].

5Allen J et al. J Natl Compr Canc Netw 2008;6(3): 285-293.

* Afatinib, nintedanib (BIBF 1120) and volasertib are investigational compounds. Their safety and efficacy have not yet been fully established.

Contacts

Boehringer Ingelheim

Corporate Communications

Media + PR

Julia Meyer-Kleinmann

Phone: +49 6132 – 77 8271

Fax: +49 6132 – 77 6601

Email: press@boehringer-ingelheim.com

The other senior-level executive appointments include Phil O’Reilly, formerly vice president of Integrated Marketing, who has assumed the post of vice president of Sales, Ethernet fabrics. His primary role is to promote the adoption of Ethernet fabric technology in enterprise data centers and in the service provider market. Charlie Foo, formerly senior director of the Brocade Partner Business Group for Asia Pacific (APAC), has been named vice president of the APAC region. He will be based in Singapore and will be responsible for developing growth strategies across APAC, which is the third largest IT market in the world according to Forrester Research.

The above changes closely align sales leadership with growth opportunities in key business areas and will create enhanced engagement between Brocade, channel partners and customers. The leaders were promoted from within the company, enabling more immediate collaboration and integration among the teams.

Regan McGrath, formerly vice president of Sales for the Americas region, has taken over the new role from Barbara Spicek. McGrath has over 25 years of IT industry experience within the end user, OEM and channel sales markets. Barbara Spicek will return to her native Germany to oversee the company’s OEM business unit across EMEA. Tom Ellery, formerly vice president of Sales for Enterprise LAN, will step into the role previously held by McGrath.

Speaking about the new appointments and vision, Ian Whiting, senior vice president of Worldwide Sales at Brocade says, “As we continue to advance towards a channel-led sales model to grow Ethernet market share globally, we need strong sales leadership with experience in all aspects of the sales cycle and go-to-market strategies to fully capitalize on growth opportunities within service provider, campus LAN, enterprise data center and storage networking environments. Regan, Phil, Charlie and Tom represent the ‘best of the best’ within our sales organization. I am fully confident in this leadership team’s ability to position Brocade well for success in the near term and beyond.”

WIND EXPO 2013

(BUSINESS WIRE)– Reed Exhibitions Japan Ltd. announced the opening of WIND EXPO 2013 – 1st Int’l Wind Energy Expo & Conference. It is the very first exhibition and conference in Japan specialised in wind energy and will be held within World Smart Energy Week 2013 – a collective gathering of 8 specialised exhibitions and conferences related to renewable/smart energy.

Concurrent Shows

• FC EXPO 2013 – 9th Int’l Hydrogen & Fuel Cell Expo
• PV EXPO 2013 – 6th Int’l Photovoltaic Power Generation Expo
• PV SYSTEM EXPO 2013 – 4th Int’l Photovoltaic Power Generation System Expo
• BATTERY JAPAN 2013 – 4th Int’l Rechargeable Battery Expo
• 3rd ECO HOUSE & ECO BUILDING EXPO
• 3rd INT’L SMART GRID EXPO
• ENETECH JAPAN 2013 – 4th Processing Technology Expo

Since the Great East Japan Earthquake and the Fukushima Daiichi nuclear power plant disaster, the attitude towards renewable energy has changed dramatically in Japan. An increasing number of people are willing to switch from nuclear to renewable sources such as Photovoltaic and Wind energy. Currently Japan’s market potential in the wind sector is around 3.6 billion* JPY (2012), but according to the statistics it is estimated to increase to 12.9 billion* JPY by 2015. With the new feed-in tariff going into effect from July 2012 and as the interest to invest in wind energy is on the rise, Reed Exhibitions Japan has decided to launch an exhibition dedicated to the wind sector parallel to the other 7 renewable/smart energy related exhibitions listed above. In fact, as the organiser of one of the world’s leading renewable/smart energy event there have been questions and requests by numerous participants of World Smart Energy Week in the past about the opening of an exhibition specialised in wind energy. Therefore, Reed Exhibitions Japan strongly believes that WIND EXPO 2013 will be valued by many present and prospective participants of World Smart Energy Week and will expand opportunities and form a greater business platform for the renewable energy industry.

*Figures from Yano Research Institute Ltd.

Opening Presentation/Briefing

An opening presentation/briefing for WIND EXPO 2013 will be held on June 11, 2012 from 2pm at Shinbashi Dai-ichi Hotel, Tokyo. The plan for the next 5 years will be revealed and many industry professionals from the industry (such as wind turbine manufacturers and wind energy generating system manufacturers) hoping to participate in WIND EXPO 2013 will present their thoughts on what to expect from the new exhibition. The event will be a perfect opportunity to learn and catch up with the latest renewable energy related products and information.

Contacts

WIND EXPO Show Management

Reed Exhibitions Japan Ltd.

Ena MASUI, +81-3-3349-8576

masuie@reedexpo.co.jp

FAX: +81-3-3344-8535

http://windexpo.jp/en/

World Smart Energy Week 2013

http://www.wsew.jp/en/